A Phase I-IIa, Multicenter, Open-Label, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Patients With Non-Muscular-Invasive Bladder Cancer

Trial Profile

A Phase I-IIa, Multicenter, Open-Label, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Patients With Non-Muscular-Invasive Bladder Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2008

At a glance

  • Drugs Mitomycin (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2008 After 10 months of follow-up, tumour recurrence has occurred in 8 (30%) patients, according to a Halozyme Therapeutics media release.
    • 30 Jun 2008 Dosing is expected to continue until September 2009, according to a Halozyme Therapeutics media release.
    • 30 Jun 2008 Induction dosing has been completed for the 15 patients receiving doses of 20,000, 60,000, 200,000 and 400,000 units and in the 12 patients receiving 800,000 units, according to a Halozyme Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top